Related Experiment Videos
Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development
J Fareed1, D Callas, D A Hoppensteadt
1Department of Pathology, Loyola University Medical Center, Maywood, Illinois 60153, USA.
The Medical Clinics of North America
|July 1, 1998
Summary
Synthetic and recombinant thrombin inhibitors are being evaluated for thrombotic and cardiovascular diseases. Further studies are needed for optimal use, focusing on dosage, monitoring, and drug interactions.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Background:
- Synthetic and recombinant thrombin inhibitors are under clinical evaluation for thrombotic and cardiovascular conditions.
- Initial trials focused on coronary indications, with recent development for prophylaxis and treatment of thromboembolic disorders.
Purpose of the Study:
- To review the clinical development of synthetic and recombinant thrombin inhibitors.
- To highlight ongoing trials and areas requiring further research for optimal drug development.
Main Methods:
- Review of clinical trial data and literature on synthetic and recombinant thrombin inhibitors.
- Analysis of current development status and future research needs.
Main Results:
- Hirudin, PEG-hirudin, and argatroban are in advanced clinical development.
- Recombinant hirudin is approved in Europe for heparin-induced thrombocytopenia (HIT) management.
- Numerous clinical trials are ongoing to establish the efficacy of these agents.
Conclusions:
- Synthetic and recombinant thrombin inhibitors show promise in managing thrombotic and cardiovascular disorders.
- Key areas for future research include dosage optimization, laboratory monitoring, neutralization strategies, and drug interactions.